-
Clinical Ophthalmology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Age-related macular degeneration: current treatments
Review
(4024) Views (778) Full article downloads
Authors: Jean Pierre Hubschman, Shantan Reddy, Steven D Schwartz
Published Date January 2009
Volume 2009:3 Pages 155 - 166
DOI: http://dx.doi.org/10.2147/OPTH.S2094
Jean Pierre Hubschman, Shantan Reddy, Steven D Schwartz
Jules Stein Eye Institute, Department of Ophthalmology, University of California, David Geffen School of Medicine, Los Angeles, California, USA
Purpose: Although important progress has been made in understanding age-related macular degeneration (AMD), management of the disease continues to be a challenge. AMD research has led to a widening of available treatment options and improved prognostic perspectives. This essay reviews these treatment options.
Design: Interpretative essay.
Methods: Literature review and interpretation.
Results: Current treatments to preserve vision in patients with non-exudative AMD include antioxidant vitamins and mineral supplementations. Exudative AMD is currently most often treated monthly with anti-VEGF intra-vitreal injections. However, investigators are beginning to experiment with combination therapy and surgical approaches in an attempt to limit the number of treatment and reduce the financial burden on the health care system.
Conclusion: By better understanding the basis and pathogenesis of AMD, newer therapies will continue to be developed that target specific pathways in patients with AMD, with the hoped for outcome of better management of the disease and improved visual acuity.
Keywords: age-related macular degeneration, VEGF, photodynamic therapy, laser, surgery
Other articles by Dr Jean-Pierre Hubschman
Readers of this article also read:
Age-related macular degeneration: experimental and emerging treatments
Antiglaucoma drugs for achieving monovision after laser in situ keratomileusis
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Etiology, prevalence, and treatment of dry eye disease
A two-week clinical evaluation of the safety of Systane® Ultra in contact lens-wearing patients
Spectacle independence and subjective satisfaction of ReSTOR® multifocal intraocular lens after cataract or presbyopia surgery in two European countries
Development of a low-cost confocal instrument to measure the axial dimensions of components in the anterior section of the eye
Revisiting corneal topography for the diagnosis of keratoconus: use of Rabinowitz's KISA% index
- Journal Indexing
See where all the Dove Press journals are indexed
- Interested in being a peer-reviewer?
Click here to register.
- Insight into 144 patients with ocular vascular events during VEGF antagonist injections
- Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
- Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
- A computer-based anaglyphic system for the treatment of amblyopia




